Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions

04/08/2021 | 07:24am EDT

By Colin Kellaher

Biogen Inc. Thursday said it signed a license agreement with Bio-Thera Solutions Ltd. to develop, manufacture and commercialize Bio-Thera's BAT1806, a proposed biosimilar to Roche Holdings AG's blockbuster rheumatoid-arthritis drug Actemra.

Biogen said it will make an upfront payment of $30 million to Guangzhou, China, biopharmaceutical company Bio-Thera, contingent upon a Phase 3 study of BAT1806 achieving satisfactory results.

The Cambridge, Mass., biopharmaceutical company said it will gain exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China, while Bio-Thera will be eligible for potential milestone payments, along with royalties on sales.

Biosimilars are near-copies of biologic drugs, such as Actemra, that are made from living cells and are analogous to generic copies of traditional pill-form medicines. Worldwide sales of Actemra topped $3 billion last year.

Biogen said it expects to complete the transaction in the second quarter.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

04-08-21 0924ET

Stocks mentioned in the article
ChangeLast1st jan.
BIO-THERA SOLUTIONS,LTD. -3.58% 22.61 End-of-day quote.-28.90%
BIOGEN INC. -1.76% 263.5 Delayed Quote.9.52%
ROCHE HOLDING AG -0.92% 306.8 Delayed Quote.0.21%
All news about BIOGEN INC.
10:50aBIOGEN  : Wedbush Adjusts Price Target on Biogen to $245 From $236, Maintains Ne..
MT
09:28aSAGE THERAPEUTICS  : Biogen Drug Candidate's Phase 2 Study in Essential Tremor M..
MT
07:39aSage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatme..
DJ
07:03aBIOGEN  : Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Control..
BU
04/09BIOGEN INC.  : Change in Directors or Principal Officers, Financial Statements a..
AQ
04/09Biogen Announces Two New Nominees for Election to Board of Directors
GL
04/09BIOGEN  : to Report First Quarter 2021 Financial Results April 22, 2021
PU
04/08BIOGEN  : RBC Capital Adjusts Biogen's Price Target to $263 From $257, Keeps Sec..
MT
04/08BIOGEN  : Bio-Thera Enter Commercialization, License Pact for Proposed Biosimila..
MT
04/08Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
DJ
More news
Financials (USD)
Sales 2021 10 584 M - -
Net income 2021 2 321 M - -
Net Debt 2021 1 289 M - -
P/E ratio 2021 17,0x
Yield 2021 -
Capitalization 40 374 M 40 374 M -
EV / Sales 2021 3,94x
EV / Sales 2022 3,76x
Nbr of Employees 9 100
Free-Float 85,9%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 34
Average target price 292,14 $
Last Close Price 268,17 $
Spread / Highest target 70,8%
Spread / Average Target 8,94%
Spread / Lowest Target -38,1%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.9.52%40 374
CSL LIMITED-6.24%91 385
WUXI BIOLOGICS (CAYMAN) INC.-0.10%55 208
SAMSUNG BIOLOGICS CO.,LTD.-5.33%45 473
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.19.13%45 356
ALEXION PHARMACEUTICALS, INC.-0.79%34 058